Share Price | Prime Medicine, Inc. Stock Analysis & Recommendation

Q: What does Prime Medicine, Inc. do?

Overview:Prime Medicine, Inc. operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.Financial Snapshot:Most recent Net Sales: 1 Million (Quarterly Results - Mar 2025) Most recent Net Profit: -52 Million (Quarterly Results - Mar 2025) Market-cap: USD 212.04 Million (Micro Cap)Key Metrics:P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -1.29 Return on Equity: -186.40% Price to Book: 1.98Contact Details:Registrar Address: Not available.

Q: Is Prime Medicine, Inc. technically bullish or bearish?

As of 10 October 2025, the technical trend for Prime Medicine, Inc. has changed from bullish to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish. However, the RSI readings are bearish for both weekly and monthly periods. The Bollinger Bands indicate a mildly bullish stance weekly and bullish monthly. Moving averages are bullish on a daily basis, while the Dow Theory shows a mildly bullish trend in both weekly and monthly time frames. The OBV is mildly bullish weekly but mildly bearish monthly. In terms of performance, the stock has returned 38.82% over the past month compared to a mere 0.31% for the S&P 500, and it has a year-to-date return of 93.49% against the S&P 500's 11.41%. Overall, the current technical stance is mildly bullish, driven by the mixed indicators across different time frames.

Results Declared: Prime Medicine, Inc. has declared results on 03 Mar 2026! Click here to unlock the latest financial performance

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

2.26 M

Shareholding (Dec 2025)

FII

7.35%

Held by 66 FIIs

DII

61.03%

Held by 31 DIIs

Promoter

12.65%

How big is Prime Medicine, Inc.?

22-Jun-2025

As of Jun 18, Prime Medicine, Inc. has a market capitalization of 212.04 million, with net sales of 3.84 million and a net profit of -202.02 million over the last four quarters. Shareholder's funds are 153.15 million, and total assets are 490.14 million.

View full answer

What does Prime Medicine, Inc. do?

22-Jun-2025

Prime Medicine, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $1 million and a net loss of $52 million as of March 2025. It has a market cap of $212.04 million and key metrics indicating significant financial challenges.

View full answer

Is Prime Medicine, Inc. technically bullish or bearish?

14-Oct-2025

As of October 10, 2025, Prime Medicine, Inc. shows a mildly bullish trend with mixed technical indicators, including bullish moving averages and MACD, but bearish RSI readings, while outperforming the S&P 500 significantly over the past month and year-to-date.

View full answer

Compare Prime Medicine, Inc. with Similar Stocks

Immatics NV Rayzebio, Inc.Replimune Group, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

With a growth in Operating Profit of 10.15%, the company declared Very Positive results in Sep 25

The company has declared positive results for the last 2 consecutive quarters
NET SALES(HY) At USD 2.34 MM has Grown at 1,019.62%
OPERATING CASH FLOW(Y) Highest at USD -109.07 MM
NET PROFIT(HY) Higher at USD -104.12 MM

Risky -

Reducing Promoter Confidence

Market Beating Performance

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 590 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.27

Return on Equity

-121.92%

Price to Book

3.65

Revenue and Profits:

Net Sales:

1 Million

(Quarterly Results - Dec 2025)

Net Profit:

-46 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-6.47%

6 Months

4.11%

1 Year

94.71%

2 Years

-49.88%

3 Years

-70.76%

4 Years

0.0%

5 Years

0.0%

Prime Medicine, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

62.54%

EBIT Growth (5y)

-253.52%

EBIT to Interest (avg)

-162.81

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.29

Sales to Capital Employed (avg)

0.02

Tax Ratio

0.07%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

43.46%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

18.09

EV to EBIT

-4.93

EV to EBITDA

-5.10

EV to Capital Employed

-29.93

EV to Sales

202.93

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-325.32%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bullish

Mildly Bullish

Moving Averages

Bullish (Daily)

KST

Bearish

Dow Theory

No Trend

Mildly Bullish

OBV

No Trend

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 38 Schemes (18.94%)

Foreign Institutions

Held by 66 Foreign Institutions (7.35%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is -63.64% vs 0.00% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is -8.98% vs 35.52% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.80",
          "val2": "2.20",
          "chgp": "-63.64%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-46.70",
          "val2": "-42.50",
          "chgp": "-9.88%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.50",
          "val2": "0.10",
          "chgp": "400.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-46.10",
          "val2": "-42.30",
          "chgp": "-8.98%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-58,004.80%",
          "val2": "-20,257.40%",
          "chgp": "-3,774.74%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 53.33% vs 0.00% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is -2.65% vs 1.11% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "4.60",
          "val2": "3.00",
          "chgp": "53.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-201.00",
          "val2": "-196.30",
          "chgp": "-2.39%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.40",
          "val2": "-0.50",
          "chgp": "180.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-201.10",
          "val2": "-195.90",
          "chgp": "-2.65%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-44,980.60%",
          "val2": "-67,873.60%",
          "chgp": "2,289.30%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY

Dec'25

Dec'24

Change(%)

Net Sales

0.80

2.20

-63.64%

Operating Profit (PBDIT) excl Other Income

-46.70

-42.50

-9.88%

Interest

0.00

Exceptional Items

0.50

0.10

400.00%

Consolidate Net Profit

-46.10

-42.30

-8.98%

Operating Profit Margin (Excl OI)

-58,004.80%

-20,257.40%

-3,774.74%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Dec 2025 is -63.64% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in quarter ended Dec 2025 is -8.98% vs 35.52% in Dec 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

4.60

3.00

53.33%

Operating Profit (PBDIT) excl Other Income

-201.00

-196.30

-2.39%

Interest

0.00

Exceptional Items

0.40

-0.50

180.00%

Consolidate Net Profit

-201.10

-195.90

-2.65%

Operating Profit Margin (Excl OI)

-44,980.60%

-67,873.60%

2,289.30%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 53.33% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is -2.65% vs 1.11% in Dec 2024

All Annual Results

Company CV

About Prime Medicine, Inc.

Prime Medicine, Inc.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available